暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股期權個股詳情
EQ240517C2500
- 0.05
- 0.000.00%
延時15分鐘行情交易中 05/16 11:53 (美東)
0.05最高價0.05最低價
0.05今開0.05昨收7張成交量53張未平倉合約數2.50行權價35.00成交額697.26%引伸波幅67.75%溢價2024/05/17到期日0.00内在价值100合約乘數1天距到期日0.05時間價值100合約規模美式期權類型0.1717Delta0.3895Gamma30.40槓桿倍數-0.0476Theta0.0000Rho5.22有效槓桿0.0002Vega
分時
- 5日
- 日K
新聞
評論
$Equillium(EQ.US$
NEWS
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
Equillium (Nasdaq: EQ) has surpassed the interim enrollment target in its Phase 3 EQUATOR study of itolizumab for acute graft-versus-host disease (aGVHD). Over 100 patients from more than 100 clinical trial sites in 12 countries are participating. Interim data will be reviewed by an independent data monitoring committee in Q3, which will trigger a thre...
NEWS
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
Equillium (Nasdaq: EQ) has surpassed the interim enrollment target in its Phase 3 EQUATOR study of itolizumab for acute graft-versus-host disease (aGVHD). Over 100 patients from more than 100 clinical trial sites in 12 countries are participating. Interim data will be reviewed by an independent data monitoring committee in Q3, which will trigger a thre...
$Equillium(EQ.US$ mad dips
$Equillium(EQ.US$ man I wish I would have trusted my gut feeling on this one
1
Analysts remain cautious about Equillium, Inc. despite better earnings and revenue projections. The 35% reduction in price target signifies this. With anticipated 11% annual revenue decline by end of 2023, skepticism about Equillium's future performance compared to recent growth and industry peers is evident.
$Equillium(EQ.US$ 今晚會漲嗎？ 有利好消息了啊
已翻譯
閱讀更多